ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma

MEK-ERK1/2 signaling is elevated in melanomas that are wild-type for both BRAF and NRAS (WT/WT), but patients are insensitive to MEK inhibitors. Stromal-derived growth factors may mediate resistance to targeted inhibitors, and optimizing the use of targeted inhibitors for WT/WT melanoma patients is...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Capparelli, Claudia, Purwin, Timothy J., Heilman, Shea A., Chervoneva, Inna, McCue, Peter A., Berger, Adam C., Davies, Michael A., Gershenwald, Jeffrey E., Krepler, Clemens, Aplin, Andrew E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168374/
https://ncbi.nlm.nih.gov/pubmed/30115691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-1001
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi